In the work by Nayir et al., the serum levels of pro-inframammary IL-18, a member of the IL-1 superfamily, were compared among breast cancer women with or without bone metastases and healthy controls, showing a decrease in IL-18 levels in response to decreased skeletal tumor burden [82]. The gene discussed is IL1A; the disease is breast carcinoma.